Grant of first POLB 001 cancer immunotherapy-induced CRS patent
Significant milestone for Poolbeg’s global intellectual property portfolio
31 March 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from IP Australia, the Australian patent office.
